Stacey Sams
Nurse Practitioner · Logan, OHNPI 1619459641
Payments from drug & device makers
Across 627 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- AstraZeneca$864
- GSK$677
- Amgen$594
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$531
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,95299%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 94 | $1,297 |
| AbbVie | 110 | $1,222 |
| AstraZeneca | 51 | $864 |
| GSK | 34 | $677 |
| Amgen(2 entities) | 57 | $594 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 44 | $531 |
| Merck | 27 | $434 |
| Bayer | 27 | $405 |
| Pfizer | 22 | $316 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $298 |
| Sanofi-aventis U.S. LLC | 21 | $277 |
| Lilly USA, LLC | 16 | $252 |
| Otsuka America Pharmaceutical, Inc. | 13 | $227 |
| Novartis | 9 | $177 |
| Johnson & Johnson | 11 | $169 |
| Astellas Pharma US Inc | 4 | $147 |
| Corcept Therapeutics | 8 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $140 |
| Abbott | 7 | $131 |
| Boehringer Ingelheim | 6 | $120 |
| Aimmune Therapeutics, Inc. | 1 | $114 |
| Exact Sciences | 5 | $100 |
| Avanir Pharmaceuticals, Inc. | 4 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Currax Pharmaceuticals LLC | 3 | $41 |
| Lucid Diagnostics Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Lundbeck LLC | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Sanofi | 1 | $12 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,052 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $124,139 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $46,849 |
| RexultiBrexpiprazole | 14 | $31,915 |
| KerendiaFinerenone | 24 | $29,134 |
| JardianceEmpagliflozin | 33 | $27,275 |
| TrulicityDulaglutide | 14 | $16,910 |
| FarxigaDapagliflozin Propanediol | 17 | $16,598 |
| MounjaroTirzepatide | 14 | $14,594 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,470 |
| MyrbetriqMirabegron | 16 | $11,246 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $11,207 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,751 |
| Celecoxib | 28 | $2,092 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,830 |
| Levothyroxine Sodium | 86 | $1,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,297 | $124,13998 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $227 | $31,91514 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $252 | $31,50428 claims |
| BayerKerendia | $405 | $29,13424 claims |
| Boehringer IngelheimJardiance | $120 | $27,27533 claims |
| AstraZenecaFarxiga | $864 | $16,59817 claims |
| GSKTrelegy Ellipta | $677 | $12,47020 claims |
| Astellas Pharma US IncMyrbetriq | $147 | $11,24616 claims |
| MerckJanumet | $434 | $6,75112 claims |
| AbbVieSynthroid | $1,222 | $1,09813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Logan
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.